Oculus Innovative Sciences Announces U.S. EPA Approval of Microcyn Disinfectant Technology; Patented Electrolysis Process Produces the Worlds First Stable Super-oxidized Water
PETALUMA, Calif. -- Hoji Alimi, founder and president of Oculus Innovative Sciences, today announced that the company has received approval from the U.S. EPA to market the companys first U.S. disinfectant product utilizing the companys Microcyn technology, as a multipurpose, hospital-grade disinfectant cleaner and food contact sanitizer for use on hard, inanimate surfaces. It is a stable, super-oxidized, pH-neutral, non-flammable and non-corrosive bactericidal, tuberculocidal and virucidal solution that is ready for use with no dilution or mixing, and requires no special handling or disposal.
Microcyn is manufactured using a sophisticated, multi-chamber electrolysis process in which ionic species are selectively produced and isolated. This process allows for the production of both a stable and pH-neutral solution while minimizing the level of chlorine in the final product. The federal EPA approval allows the company to market its label claims and enter into negotiations with distributors for commercialization purposes.
The first commercialized product formulated with Microcyn technology for use in the United States will be Cidalcyn Hospital Grade Disinfectant. It will effectively disinfect hard, non-porous surfaces such as non-critical medical devices, surgical beds/tables, dental irrigation equipment, and anesthesia machines. It is also for use in the consumer market.
The company also received CE approval for its Microcyn technology in Europe this past spring and Ministry of Health approval in Mexico in 2003. Oculus introduced its first U.S. product, Vetericyn Wound Spray for animals, also formulated with the patented Microcyn technology, in July.
Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative life sciences and disruptive technologies that globally re-define the disinfectant and antiseptic markets. With a primary focus on anti-infective and wound management technologies, the company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V.
Source: Oculus Innovative Sciences
Pioneering Advances in Sterilization: The Future of Infection Control
November 28th 2024Germitec, STERIS, ASP, and Zuno Medical are pioneering sterilization advancements with groundbreaking technologies that enhance SPD workflows, improve patient safety, and redefine infection control standards.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
